Therefore, targeting YAP/TAZ such as by the use of TEAD inhibitors or inhibitors/antibodies for unknown mechanisms in combination with EGFR-targeting therapy may provide novel therapeutic approaches for preventing cancer recurrence and progression (Figure 2, Figure 3 and Figure 4). Here, WWTR1 is linked to cancer.